Publications

Dan Zandberg

Nilsen ML, Belsky MA, Scheff N, Johnson JT, Zandberg DP, Skinner H, Ferris R. Late and Long-Term Treatment-Related Effects and Survivorship for Head and Neck Cancer Patients. Curr Treat Options Oncol. 2020 Oct 3;21(12):92. doi: 10.1007/s11864-020-00797-x. PubMed PMID: 33009956.
Cohen EEW, Bell RB, Bifulco CB, Burtness B, Gillison ML, Harrington KJ, Le QT, Lee NY, Leidner R, Lewis RL, Licitra L, Mehanna H, Mell LK, Raben A, Sikora AG, Uppaluri R, Whitworth F, Zandberg DP, Ferris RL. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC). J Immunother Cancer. 2019 Jul 15;7(1):184. doi: 10.1186/s40425-019-0662-5. PubMed PMID: 31307547; PMCID: PMC6632213.
Zandberg DP, Tallon LJ, Nagaraj S, Sadzewicz LK, Zhang Y, Strome MB, Zhao XE, Vavikolanu K, Zhang X, Papadimitriou JC, Hubbard FA, Bentzen SM, Strome SE, Fraser CM. Intratumor genetic heterogeneity in squamous cell carcinoma of the oral cavity. Head Neck. 2019 Aug;41(8):2514-2524. doi: 10.1002/hed.25719. PubMed PMID: 30869813.
Segal NH, Ou SI, Balmanoukian A, Fury MG, Massarelli E, Brahmer JR, Weiss J, Schöffski P, Antonia SJ, Massard C, Zandberg DP, Khleif SN, Xiao F, Rebelatto MC, Steele KE, Robbins PB, Angra N, Song X, Abdullah S, Butler M. Safety and efficacy of durvalumab in patients with head and neck squamous cell carcinoma: results from a phase I/II expansion cohort. Eur J Cancer. 2019 Mar;109154-161. doi: 10.1016/j.ejca.2018.12.029. PubMed PMID: 30731276.
Zandberg DP, Algazi AP, Jimeno A, Good JS, Fayette J, Bouganim N, Ready NE, Clement PM, Even C, Jang RW, Wong S, Keilholz U, Gilbert J, Fenton M, Braña I, Henry S, Remenar E, Papai Z, Siu LL, Jarkowski A, Armstrong JM, Asubonteng K, Fan J, Melillo G, Mesía R. Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: Results from a single-arm, phase II study in patients with ≥25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy. Eur J Cancer. 2019 Jan;107142-152. doi: 10.1016/j.ejca.2018.11.015. PubMed PMID: 30576970.
Siu LL, Even C, Mesía R, Remenar E, Daste A, Delord JP, Krauss J, Saba NF, Nabell L, Ready NE, Braña I, Kotecki N, Zandberg DP, Gilbert J, Mehanna H, Bonomi M, Jarkowski A, Melillo G, Armstrong JM, Wildsmith S, Fayette J. Safety and Efficacy of Durvalumab With or Without Tremelimumab in Patients With PD-L1-Low/Negative Recurrent or Metastatic HNSCC: The Phase 2 CONDOR Randomized Clinical Trial. JAMA Oncol. 2019 Feb 1;5(2):195-203. doi: 10.1001/jamaoncol.2018.4628. PubMed PMID: 30383184; PMCID: PMC6439564.
Zandberg DP, Ferris RL. Window Studies in Squamous Cell Carcinoma of the Head and Neck: Values and Limits. Curr Treat Options Oncol. 2018 Oct 27;19(12):68. doi: 10.1007/s11864-018-0587-0. PubMed PMID: 30367283; PMCID: PMC6564676.
Scilla KA, Zandberg DP, Bentzen SM, Mainor C, Heath J, Ioffe OB, Cellini AL, Edelman MJ, Riedel DJ, Feliciano JL. Case-control study of PD-1, PD-L1 and B7-H3 expression in lung cancer patients with and without human immunodeficiency virus (HIV) infection. Lung Cancer. 2018 Sep;12387-90. doi: 10.1016/j.lungcan.2018.06.028. PubMed PMID: 30089601.

<< Investigators Search

Top